AR109688A1 - Compuestos de indazol para uso en lesiones de tendones y/o ligamentos - Google Patents
Compuestos de indazol para uso en lesiones de tendones y/o ligamentosInfo
- Publication number
- AR109688A1 AR109688A1 ARP170102603A ARP170102603A AR109688A1 AR 109688 A1 AR109688 A1 AR 109688A1 AR P170102603 A ARP170102603 A AR P170102603A AR P170102603 A ARP170102603 A AR P170102603A AR 109688 A1 AR109688 A1 AR 109688A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- once
- halogen
- hydroxyl
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Además se proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica utilizada en el tratamiento de las lesiones de tendón. Reivindicación 1: Un compuesto de la fórmula (1) en forma libre ó en forma de sal farmacéuticamente aceptable, caracterizada porque, R¹ se selecciona a partir de alquilo C₁₋₃, halógeno y alcoxilo C₁₋₃; R² se selecciona independientemente entre alquilo C₁₋₃ y halógeno; n es 1 ó 2, R³ se selecciona a partir de H y alquilo C₁₋₃, y R⁴ se selecciona a partir de un cicloalquilo C₄₋₆ sustituido opcionalmente una vez o más de una vez por R⁵; un anillo no aromático heterocíclico de 5 ó 6 miembros que comprende al menos un heteroátomo seleccionado entre N, O ó S, sustituido opcionalmente una vez o más de una vez independientemente por hidroxilo, alquilo C₁₋₃, alcoxilo C₁₋₃; en donde R⁴ no es 4-hidroxiciclohexilo o tetrahidrofurano; o R³ y R⁴ junto con el átomo N al cual están unidos, forman un anillo no aromático heterocíclico de 4, 5 ó 6 miembros que comprende opcionalmente un heteroátomo adicional seleccionado entre N, O ó S, dicho anillo se sustituye una vez o más de una vez por R⁶; R⁵ se selecciona independientemente entre hidroxilo, haloalquilo C₁₋₃, halógeno, alquilo C₁₋₂, fenilo, bencilo, cicloalquilo C₃₋₆, ciano; R⁶ se selecciona independientemente entre halógeno, hidroxialquilo C₁₋₃, C₍O₎NH₂, hidroxilo, alquilo C₁₋₃, ciano, haloalquilo C₁₋₃.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662398869P | 2016-09-23 | 2016-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR109688A1 true AR109688A1 (es) | 2019-01-16 |
Family
ID=60084023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170102603A AR109688A1 (es) | 2016-09-23 | 2017-09-21 | Compuestos de indazol para uso en lesiones de tendones y/o ligamentos |
Country Status (38)
Country | Link |
---|---|
US (1) | US10112907B2 (es) |
EP (1) | EP3515894B1 (es) |
JP (1) | JP7007374B2 (es) |
KR (1) | KR102490953B1 (es) |
CN (1) | CN109715608B (es) |
AR (1) | AR109688A1 (es) |
AU (1) | AU2017332867B2 (es) |
BR (1) | BR112019005578A2 (es) |
CA (1) | CA3033249A1 (es) |
CL (1) | CL2019000727A1 (es) |
CO (1) | CO2019002616A2 (es) |
CR (1) | CR20190145A (es) |
CU (1) | CU24553B1 (es) |
CY (1) | CY1124301T1 (es) |
DK (1) | DK3515894T3 (es) |
DO (1) | DOP2019000071A (es) |
EA (1) | EA038510B1 (es) |
EC (1) | ECSP19019589A (es) |
ES (1) | ES2878585T3 (es) |
HR (1) | HRP20211006T1 (es) |
HU (1) | HUE054910T2 (es) |
IL (1) | IL265066B (es) |
JO (1) | JOP20190054B1 (es) |
LT (1) | LT3515894T (es) |
MX (1) | MX2019003362A (es) |
MY (1) | MY196425A (es) |
PE (1) | PE20190657A1 (es) |
PH (1) | PH12019500327A1 (es) |
PL (1) | PL3515894T3 (es) |
PT (1) | PT3515894T (es) |
RS (1) | RS62145B1 (es) |
RU (1) | RU2749547C2 (es) |
SG (1) | SG11201901146SA (es) |
SI (1) | SI3515894T1 (es) |
TW (1) | TWI651308B (es) |
UY (1) | UY37412A (es) |
WO (1) | WO2018055550A1 (es) |
ZA (1) | ZA201900860B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190053A1 (ar) * | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
CN113260364A (zh) | 2019-01-11 | 2021-08-13 | 诺华股份有限公司 | 用于治疗化脓性汗腺炎的lta4h抑制剂 |
TW202342048A (zh) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用lou064治療化膿性汗腺炎之方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002220051B2 (en) * | 2000-11-02 | 2007-05-24 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
AU2002222293A1 (en) | 2000-12-19 | 2002-07-01 | Smithkline Beecham P.L.C. | Pyrazolo(3,4-c)pyridines as gsk-3 inhibitors |
WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
FR2871158A1 (fr) | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
DE102004028862A1 (de) | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
PE20060373A1 (es) | 2004-06-24 | 2006-04-29 | Smithkline Beecham Corp | Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2 |
FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
WO2008104473A2 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Pyrazolopyriidine derivatives and their use as kinase inhibitors |
BRPI0811065A2 (pt) | 2007-06-08 | 2014-12-02 | Abbott Lab | Indazóis 5-heteroaril substituídos como inibidores de quinase |
US20110237633A1 (en) | 2008-12-11 | 2011-09-29 | Bijoy Panicker | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
US8846673B2 (en) | 2009-08-11 | 2014-09-30 | Bristol-Myers Squibb Company | Azaindazoles as kinase inhibitors and use thereof |
JP2013542960A (ja) | 2010-11-08 | 2013-11-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド | 脂肪酸シンターゼ阻害剤 |
CN103403002B (zh) * | 2011-02-24 | 2016-06-22 | 内尔维阿诺医学科学有限公司 | 作为激酶抑制剂的噻唑基苯基-苯磺酰氨基衍生物 |
US20140107151A1 (en) | 2011-05-17 | 2014-04-17 | Principia Biophama Inc. | Tyrosine kinase inhibitors |
UA112028C2 (uk) * | 2012-12-14 | 2016-07-11 | Пфайзер Лімітед | Похідні імідазопіридазину як модулятори гамка-рецептора |
TWI629275B (zh) * | 2013-03-13 | 2018-07-11 | 賽諾菲公司 | N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺及其作為醫藥之用途 |
-
2017
- 2017-09-21 BR BR112019005578A patent/BR112019005578A2/pt active Search and Examination
- 2017-09-21 KR KR1020197010512A patent/KR102490953B1/ko active IP Right Grant
- 2017-09-21 ES ES17784404T patent/ES2878585T3/es active Active
- 2017-09-21 EP EP17784404.0A patent/EP3515894B1/en active Active
- 2017-09-21 AR ARP170102603A patent/AR109688A1/es unknown
- 2017-09-21 MX MX2019003362A patent/MX2019003362A/es unknown
- 2017-09-21 CU CU2019000028A patent/CU24553B1/es unknown
- 2017-09-21 JO JOP/2019/0054A patent/JOP20190054B1/ar active
- 2017-09-21 WO PCT/IB2017/055735 patent/WO2018055550A1/en unknown
- 2017-09-21 CR CR20190145A patent/CR20190145A/es unknown
- 2017-09-21 DK DK17784404.0T patent/DK3515894T3/da active
- 2017-09-21 PL PL17784404T patent/PL3515894T3/pl unknown
- 2017-09-21 HU HUE17784404A patent/HUE054910T2/hu unknown
- 2017-09-21 AU AU2017332867A patent/AU2017332867B2/en active Active
- 2017-09-21 CA CA3033249A patent/CA3033249A1/en active Pending
- 2017-09-21 US US15/711,984 patent/US10112907B2/en active Active
- 2017-09-21 MY MYPI2019000713A patent/MY196425A/en unknown
- 2017-09-21 LT LTEP17784404.0T patent/LT3515894T/lt unknown
- 2017-09-21 TW TW106132361A patent/TWI651308B/zh active
- 2017-09-21 PE PE2019000680A patent/PE20190657A1/es unknown
- 2017-09-21 EA EA201990766A patent/EA038510B1/ru not_active IP Right Cessation
- 2017-09-21 JP JP2019515633A patent/JP7007374B2/ja active Active
- 2017-09-21 RS RS20210833A patent/RS62145B1/sr unknown
- 2017-09-21 SG SG11201901146SA patent/SG11201901146SA/en unknown
- 2017-09-21 UY UY0001037412A patent/UY37412A/es unknown
- 2017-09-21 SI SI201730834T patent/SI3515894T1/sl unknown
- 2017-09-21 CN CN201780057662.4A patent/CN109715608B/zh active Active
- 2017-09-21 PT PT177844040T patent/PT3515894T/pt unknown
- 2017-09-21 RU RU2019111883A patent/RU2749547C2/ru active
-
2019
- 2019-02-11 ZA ZA2019/00860A patent/ZA201900860B/en unknown
- 2019-02-15 PH PH12019500327A patent/PH12019500327A1/en unknown
- 2019-02-26 IL IL265066A patent/IL265066B/en active IP Right Grant
- 2019-03-20 CL CL2019000727A patent/CL2019000727A1/es unknown
- 2019-03-20 DO DO2019000071A patent/DOP2019000071A/es unknown
- 2019-03-20 EC ECSENADI201919589A patent/ECSP19019589A/es unknown
- 2019-03-21 CO CONC2019/0002616A patent/CO2019002616A2/es unknown
-
2021
- 2021-06-24 HR HRP20211006TT patent/HRP20211006T1/hr unknown
- 2021-07-05 CY CY20211100601T patent/CY1124301T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20212077A1 (es) | Nuevos compuestos sulfonamida de carboxamida | |
CR20170563A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
CY1120899T1 (el) | Παραγωγα 1,2,4-οξαδιαζολιου ως ανοσοτροποποιητες | |
AR107927A1 (es) | Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento | |
PE20170127A1 (es) | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas | |
CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
AR095034A1 (es) | El uso de los agonistas del receptor 2 del péptido formilo para el tratamiento de las enfermedades inflamatorias oculares | |
AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
AR054799A1 (es) | Derivados de oxindol | |
AR101177A1 (es) | Inhibidores de la syk | |
CO2021006482A2 (es) | Ureas cíclicas | |
DOP2018000196A (es) | Metodos para tratar la depresion con antagonistas del receptor de orexina-2 | |
AR097866A1 (es) | Derivados de 4-azaindol | |
PE20240930A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
AR109688A1 (es) | Compuestos de indazol para uso en lesiones de tendones y/o ligamentos | |
EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
AR095858A1 (es) | COMBINACIONES DE LIGANDOS DE RECEPTORES ADRENÉRGICOS a-2 Y RECEPTORES SIGMA | |
AR109108A1 (es) | Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2 | |
CR11584A (es) | Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina | |
CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
AR107937A1 (es) | Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer | |
PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |